Chevy Chase Trust Holdings Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,702,270 shares of the company’s stock after buying an additional 1,480 shares during the quarter. Johnson & Johnson accounts for 1.6% of Chevy Chase Trust Holdings Inc.’s portfolio, making the stock its 5th biggest holding. Chevy Chase Trust Holdings Inc.’s holdings in Johnson & Johnson were worth $377,558,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. BlackRock Inc. raised its stake in shares of Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after purchasing an additional 130,437 shares in the last quarter. FMR LLC raised its stake in shares of Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares in the last quarter. Finally, Capital World Investors raised its stake in shares of Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after purchasing an additional 1,050,000 shares in the last quarter. Hedge funds and other institutional investors own 67.23% of the company’s stock.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.22% of the company’s stock.
A number of brokerages recently weighed in on JNJ. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective on the stock in a research note on Thursday, January 11th. Stifel Nicolaus raised their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th. BMO Capital Markets raised their price objective on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Jefferies Group set a $161.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, March 23rd. Finally, TheStreet downgraded Johnson & Johnson from an “a” rating to a “c+” rating in a research note on Monday, March 26th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $144.58.
Shares of NYSE JNJ opened at $128.10 on Monday. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $343,679.78, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 2.04 and a beta of 0.74. Johnson & Johnson has a 12 month low of $120.95 and a 12 month high of $148.32.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. The company had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.58 EPS. research analysts forecast that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
WARNING: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/09/johnson-johnson-jnj-holdings-raised-by-chevy-chase-trust-holdings-inc.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.